Breast Cancer Now media statements
We respond to announcement from NHS England of a new Innovative Medicines Fund
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, responded to the announcement from NHS England of a new Innovative Medicines F...
We respond to the latest census of clinical oncologists from The Royal College of Radiologists
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, responded to the latest census of clinical oncologists from The Royal College ...
We welcome new treatment method for HER2 positive breast cancer for use on Scotland’s NHS
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to NICE decision to recommend tucatinib with trastuzumab and capecitabine for routine use on the NHS
The National Institute for Health and Care Excellence (NICE) has today announced its decision to recommend breast cancer treatment tucatinib...
We respond to today's NHSE Breast Screening Programme 2020-21 report
Key findings: In 2020/21, around 936,000 fewer women in England were screened for breast cancer compared to the previous year. This is a dec...
We respond to the latest COVID-19 guidance
Mia Rosenblatt, Associate Director of Policy, Evidence and Influencing at Breast Cancer Now, said:
We respond to a new study looking at breast pain and breast cancer
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
We respond to 'The projected impact of the COVID-19 lockdown on breast cancer deaths in England due to the cessation of population screening: a national estimation’
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to NHS England breast cancer waiting times: December 2021
Mia Rosenblatt, Associate Director of Policy, Evidence and Influencing at Breast Cancer Now, said:
Responding to new research that pembrolizumab cuts the risk of triple negative breast cancer returning by 37%
New research findings published in the New England Journal of Medicine found that pembrolizumab, if given in combination with chemo before s...
We respond to House of Commons library analysis revealing record numbers of women facing delays to see an NHS cancer specialist
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said: